FDA WARNING_LETTER - inspire.clinic - August 01, 2025

On September 9, 2025, the FDA issued a warning letter to inspire.clinic, located in Grand Prairie, Texas, following a review of the company"s website in August 2025. The investigation revealed that the clinic was marketing compounded versions of semaglutide and tirzepatide using false or misleading claims. Specifically, the website suggested these products were "similar" or "comparable" to FDA-approved drugs such as Ozempic and Mounjaro. Under the Federal Food, Drug, and Cosmetic Act, compounded drugs do not undergo the same FDA approval process as brand-name medications. Consequently, advertising them as equivalent to approved drugs is considered a violation of federal law because it misleads consumers about the products" status and safety. The FDA noted that the clinic"s actions involved the illegal distribution of misbranded drugs across state lines. The agency has directed inspire.clinic to take immediate steps to correct these violations, including removing the deceptive marketing language. The company is required to submit a written response within 15 working days outlining its corrective actions and plans to prevent future issues. Failure to adequately address these concerns may lead to more severe regulatory consequences, such as product seizures or court-ordered injunctions. This letter emphasizes the clinic"s responsibility to ensure its business practices comply with all federal health regulations.